Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | HPGDS | O60760 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13099128 | 0.87 | HRH3 (0.57) | ADRA1AHRH3NPC1RAB9A | |
| SCHEMBL6135038 | 0.83 | HDAC3 (0.47) | HRH3ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL13099148 | 0.82 | ADORA3 (0.46) | ADRA1AHRH3ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL7325011 | 0.80 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2HPGDHPGDSNPC1 | |
| SCHEMBL13098926 | 0.79 | MAP4K4 (0.45) | ADRA1A | |
| SCHEMBL3598305 | 0.78 | UBE2T (0.60) | ALDH1A1SMN1; SMN2HPGDHPGDSNPC1 | |
| SCHEMBL13098938 | 0.76 | ADRA1A (0.41) | ADRA1A | |
| SCHEMBL31747418 | 0.73 | HRH3 (0.55) | HRH3 | |
| SCHEMBL4930304 | 0.72 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2HPGDHPGDSNPC1 | |
| SCHEMBL5638622 | 0.72 | RAB9A (0.60) | ALDH1A1SMN1; SMN2HPGDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | VIP, ANPEP, NPEPPS | ADRA1A 4341/4885HRH3 2183/4885ALDH1A1 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.